DWTX — Dogwood Therapeutics, Inc.

Open full analysis

Chart, dilution, float and news for DWTX in the TickerWise workspace.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ Capital Market
• Employees: 12
• Website: https://www.dwtx.com

Latest SEC filings for DWTX

• 2026-08-14SCHEDULE 13G/A
• 2026-05-15SCHEDULE 13G
• 2026-04-27ARS
• 2025-11-0710-Q
• 2025-11-068-K
• 2025-10-16S-3/A
• 2025-10-098-K
• 2025-10-01S-3
• 2025-09-298-K
• 2025-08-138-K

Latest DWTX news

• 2026-10-19Dogwood Therapeutics secures $5M investment from largest shareholder; shares rise Read article
• 2026-10-06Dogwood to Participate in the 2026 Maxim Growth Summit Read article

Open full analysis

Educational tool only — not investment advice.